The continuous glucose monitoring device (CGMD) market is projected to reach US$33.21 billion by 2031 from US$12.71 billion in 2024. The market is estimated to register a CAGR of 14.9% during 2025-2031. Major factors driving the market growth include a rising global prevalence of diabetes, technological advancements in CGM devices, and benefits over conventional glucose monitoring are propelling the adoption of continuous glucose monitoring device (CGMD). Further, integration with insulin delivery and AI-driven decision support will likely boost the market during the forecast period. However, the high cost and limited reimbursement and user comfort and wearability challenges are among the market deterrents.

Continuous glucose monitoring (CGM) devices offer substantial and clinically meaningful advantages over conventional blood glucose monitoring methods, fundamentally transforming diabetes management for millions worldwide. Unlike traditional approaches that rely on periodic finger-prick tests, CGMs provide real-time, continuous measurement of glucose levels via minimally invasive sensors, allowing users and clinicians to assess glucose variability and trends rather than single data points. Recent clinical studies report that CGM use achieves reductions in HbA1c levels ranging from 0.25% to 3.0% and improves "time in range" (the percentage of time glucose remains within target levels) by 15-34%, both of which are associated with lower risk of diabetes complications and improved long-term outcomes.

One of the most impactful developments in CGM technology is its ability to deliver real-time alerts for hypoglycemia and hyperglycemia. These alarms enable immediate intervention, such as prompt carbohydrate consumption or insulin dose adjustment, drastically reducing the frequency and severity of dangerous episodes. Studies show that low-glucose prediction algorithms integrated in newer CGMs can reduce time below range by up to 92% compared to no alerts and 47% compared to standard alerts, significantly improving safety, especially during sleep or for patients at high risk of hypoglycemia. Additionally, nocturnal low-glucose prediction technology has demonstrated a 37% reduction in nightly time spent below the safe glucose threshold, providing substantial protection during vulnerable hours.

CGMs are transformational educational tools, motivating personalized lifestyle change by mapping dietary intake, physical activity, medication response, and stress factors to corresponding glucose fluctuations. This ongoing visual feedback enhances self-management skills and patient engagement, offering insights far superior to conventional education methods that lack immediate and personalized physiological data. Such continuous data streams enable dynamic diabetes management, allowing patients and healthcare providers to make proactive, evidence-based decisions, adjust therapy between clinic visits, and recognize previously unnoticed patterns such as postprandial spikes or nocturnal highs.

CGM also delivers a detailed and comprehensive glucose profile for healthcare providers, including metrics such as time in range, hypoglycemia/hyperglycemia frequency, and glycemic variability. This enables more precise treatment intensification, risk stratification, and preventive strategies to lower hospitalization rates and avoid severe complications. The capability to remotely monitor patient data, enhanced by integrated wireless data transmission and cloud-based storage, streamlines care delivery and boosts adherence. This is particularly beneficial for vulnerable groups, including children, the elderly, pregnant women, and individuals with impaired awareness of hypoglycemia.

CGMs eliminate the practical and psychological burden of frequent finger sticks, a limitation that impaired adherence and quality of life with earlier methods. Children particularly value this "finger-prick-free" approach, and patients undergoing intensive therapy report higher treatment satisfaction and long-term device retention rates despite cost and device complexity challenges.

CGM encompasses dramatic improvements in glycemic control statistics, hypoglycemia prevention, patient empowerment through real-time data, holistic healthcare-team support with actionable metrics, and enhanced overall quality of life. With these clinically validated benefits, international diabetes care standards strongly recommend CGM for type 1 diabetes and expanding indications for type 2 diabetes. This reinforces CGM's role as a cornerstone of modern diabetes care.

The comparative company analysis evaluates and categorizes the continuous glucose monitoring device (CGMD) market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global continuous glucose monitoring device (CGMD) market. The key market players are Abbott Laboratories; Dexcom Inc., Ypsomed Holding AG, Medtronic, F. Hoffmann-La Roche Ltd, Senseonics Holdings Inc, i-SENS Inc., A. Menarini Diagnostics s.r.l, Tandem Diabetes Care, Inc., and Medtrum Technologies Inc.

Based on product, the continuous glucose monitoring device (CGMD) market is segmented into sensors, transmitters, and receivers. The sensors segment held the largest share of the market in 2024.

By application, the market is categorized into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment accounted for the largest continuous glucose monitoring device (CGMD) market share in 2024.

By testing sites, the market is categorized into fingertip testing and alternate site testing. The fingertip testing segment accounted for the largest share of the continuous glucose monitoring device (CGMD) market in 2024. Fingertip blood glucose testing, also known as self-monitoring of blood glucose (SMBG), has long been the foundation of diabetes management. It offers direct capillary blood readings by pricking a finger and applying a drop to a meter. Though CGMs increasingly dominate due to their continuous and trend-focused data, finger sticks remain essential for calibration (in some CGMs) and confirmation during rapid glucose changes or suspected measurement errors.

Accuracy remains one of SMBG's advantages. Modern fingerstick meters typically demonstrate lower Mean Absolute Relative Difference (MARD), often in the 5-6% range, compared to around 8-9% for top-tier CGMs such as the Dexcom G7 and FreeStyle Libre 3. This edge in accuracy is particularly valuable in situations requiring precise glucose readings, such as confirming hypoglycemia or calibrating CGMs. Lag time and interstitial vs. capillary fluid differences remain key distinctions. CGMs measure interstitial fluid glucose, which typically lags behind blood glucose by ~5-15 minutes. Behind actual blood glucose, Fingerstick testing provides immediate access to true capillary glucose levels, making it invaluable when rapid changes occur or device alerts seem inconsistent with symptoms.

Regarding end user, the continuous glucose monitoring device (CGMD) market is segmented into hospitals and clinics, and self or homecare. The self or homecare segment held the largest share of the continuous glucose monitoring device (CGMD) market in 2024.

Companies operating in the continuous glucose monitoring device (CGMD) market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key continuous glucose monitoring device (CGMD) market players are listed below.

In July 2025, Abbott obtained FDA approvals for two new over-the-counter (OTC) continuous glucose monitoring systems, Lingo and Libre Rio. These are based on the FreeStyle Libre technology, expanding access to glucose monitoring beyond traditional diabetes management to general health and wellness. This is a major step in consumerizing IoT medical devices.

In July 2025, DexCom, Inc. announced it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the US. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now take a photo of their food in the app, where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the US's only prescription continuous glucose monitors to support photo logging.

In April 2025, DexCom, Inc. announced the FDA has cleared the Dexcom G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.